Literature DB >> 11179328

Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.

R Borrow1, N Andrews, D Goldblatt, E Miller.   

Abstract

The antibody data supporting the use of meningococcal serogroup C conjugate (MCC) vaccines in the United Kingdom were generated by serum bactericidal assay (SBA) using rabbit complement (rSBA). This may give higher titers than those obtained with human complement (hSBA), for which the "gold standard" correlate of protection for meningococcal C disease is a titer of > or =4. Comparison of rSBA and hSBA titers in sera from unvaccinated adults with an rSBA titer of > or =8 showed that for 93% (27 of 29) the titer was > or =4 by hSBA, confirming natural protection. Furthermore, sera from MCC vaccinees showed that an rSBA titer of <8 or > or =128 discriminated susceptibility and protection well (85% with rSBA titers of <8 had hSBA titers of <4, and 99% with rSBA titers of > or =128 had hSBA titers of > or =4). However, discrimination was poor in the rSBA titer range 8 to 64, with only 60% having hSBA titers of > or =4. In such cases we propose that protection can be assumed if there is a fourfold rise in titer between pre- and postvaccination sera or if there is a characteristic booster response to a polysaccharide challenge dose with, if available, evidence of antibody avidity maturation or an hSBA titer of result > or =4. Applying these criteria to toddlers, 10 to 40% of whom had titers in the range 8 to 64 after a single dose of MCC vaccine, showed that 94% had a fourfold rise in titer, including 98% of those in the titer range 8 to 64. In addition, of those with titers of <128 post-MCC vaccination, 90% had titers of > or =128 after a 10-microg polysaccharide booster dose, compared with only 7% of unprimed age-matched toddlers given a full 50-microg dose. Furthermore, the increase in geometric mean avidity index pre- and postbooster was independent of post-primary MCC titer. These results indicated that the majority of toddlers with an rSBA titer between 8 and 64, and some of those with an hSBA result of <4, have mounted a protective immune response with the induction of immunological memory.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11179328      PMCID: PMC98057          DOI: 10.1128/IAI.69.3.1568-1573.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  Lack of immunity in university students before an outbreak of serogroup C meningococcal infection.

Authors:  G R Jones; J N Williams; M Christodoulides; K Jolley; J E Heckels
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

Review 2.  Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis.

Authors:  J Eskola; J Ward; R Dagan; D Goldblatt; F Zepp; C A Siegrist
Journal:  Lancet       Date:  1999-12-11       Impact factor: 79.321

3.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.

Authors:  S Black; H Shinefield; B Fireman; E Lewis; P Ray; J R Hansen; L Elvin; K M Ensor; J Hackell; G Siber; F Malinoski; D Madore; I Chang; R Kohberger; W Watson; R Austrian; K Edwards
Journal:  Pediatr Infect Dis J       Date:  2000-03       Impact factor: 2.129

4.  Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults.

Authors:  P Richmond; D Goldblatt; P C Fusco; J D Fusco; I Heron; S Clark; R Borrow; F Michon
Journal:  Vaccine       Date:  1999-11-12       Impact factor: 3.641

5.  Kinetics of antibody response to Haemophilus influenzae type b vaccines. Pennridge Pediatric Associates.

Authors:  D V Madore; C L Johnson-Kraines; E P Rothstein; D H Smith
Journal:  Curr Med Res Opin       Date:  1999       Impact factor: 2.580

6.  Induction of immunological memory in UK infants by a meningococcal A/C conjugate vaccine.

Authors:  R Borrow; A J Fox; P C Richmond; S Clark; F Sadler; J Findlow; R Morris; N T Begg; K A Cartwright
Journal:  Epidemiol Infect       Date:  2000-06       Impact factor: 2.451

7.  Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.

Authors:  P Richmond; R Borrow; D Goldblatt; J Findlow; S Martin; R Morris; K Cartwright; E Miller
Journal:  J Infect Dis       Date:  2000-11-14       Impact factor: 5.226

8.  Seven-week interval between acquisition of a meningococcus and the onset of invasive disease. A case report.

Authors:  K R Neal; J S Nguyen-van-Tam; R C Slack; E B Kaczmarski; A White; D A Ala'Aldeen
Journal:  Epidemiol Infect       Date:  1999-12       Impact factor: 2.451

9.  Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger.

Authors:  G Campagne; A Garba; P Fabre; A Schuchat; R Ryall; D Boulanger; M Bybel; G Carlone; P Briantais; B Ivanoff; B Xerri; J P Chippaux
Journal:  Pediatr Infect Dis J       Date:  2000-02       Impact factor: 2.129

10.  Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccine.

Authors:  R Borrow; P Richmond; E B Kaczmarski; A Iverson; S L Martin; J Findlow; M Acuna; E Longworth; R O'Connor; J Paul; E Miller
Journal:  FEMS Immunol Med Microbiol       Date:  2000-05
View more
  98 in total

1.  Identification of Neisseria meningitidis serogroups Y and W135 by siaD nucleotide sequence analysis.

Authors:  C Lewis; S C Clarke
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

2.  Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source.

Authors:  C J Gill; S Ram; J A Welsch; L Detora; A Anemona
Journal:  Vaccine       Date:  2011-11-07       Impact factor: 3.641

3.  Characterization of MspA, an immunogenic autotransporter protein that mediates adhesion to epithelial and endothelial cells in Neisseria meningitidis.

Authors:  D P J Turner; A G Marietou; L Johnston; K K L Ho; A J Rogers; K G Wooldridge; D A A Ala'Aldeen
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

4.  Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.

Authors:  Lisa A Lewis; David M Vu; Dan M Granoff; Sanjay Ram
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

5.  Immunogenicity and safety of meningococcal C conjugate vaccine in children and adolescents infected and uninfected with HIV in Rio de Janeiro, Brazil.

Authors:  Ana Cristina C Frota; Lucimar G Milagres; Lee H Harrison; Bianca Ferreira; Daniela Menna Barreto; Gisele S Pereira; Aline C Cruz; Wania Pereira-Manfro; Ricardo Hugo de Oliveira; Thalita F Abreu; Cristina B Hofer
Journal:  Pediatr Infect Dis J       Date:  2015-05       Impact factor: 2.129

6.  Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.

Authors:  Jian-li Hu; Hong Tao; Jing-xin Li; Wei-ming Dai; Bin Song; Jin-fang Sun; Pei Liu; Jie Tang; Wen-yu Liu; Shi-yuan Wang; Feng-cai Zhu
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals.

Authors:  Paul Balmer; Michelle Falconer; Paula McDonald; Nick Andrews; Emily Fuller; Christine Riley; Edward Kaczmarski; Raymond Borrow
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

8.  Immunization of female mice with glycoconjugates protects their offspring against encapsulated bacteria.

Authors:  Margret Y Richter; Håvard Jakobsen; Alda Birgisdottir; Jean-François Haeuw; Ultan F Power; Giuseppe Del Giudice; Antonella Bartoloni; Ingileif Jonsdottir
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 9.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

10.  Purified capsular polysaccharide of Neisseria meningitidis serogroup A as immune potentiator for antibody production.

Authors:  Tamara Menéndez; Tania Carmenate; Yoelys Cruz-Leal; Edelgis Coizeau; Evelyn Caballero; Daniel Bello; María Guirola; Anabel Alvarez; Gerardo Guillén
Journal:  Curr Microbiol       Date:  2009-09-23       Impact factor: 2.188

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.